This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2004 Apr 7;291(13):1563; author reply 1563-4.

doi: 10.1001/jama.291.13.1563-a.

Predictors of clinical response of non-small cell cancer to gefitinib

Andrea Ardizzoni, Marcello Tiseo

PMID: 15069041
DOI: 10.1001/jama.291.13.1563-a

Comment

Predictors of clinical response of non-small cell cancer to gefitinib

Andrea Ardizzoni et al. JAMA. 2004.

. 2004 Apr 7;291(13):1563; author reply 1563-4.

doi: 10.1001/jama.291.13.1563-a.

Authors

Andrea Ardizzoni, Marcello Tiseo

PMID: 15069041
DOI: 10.1001/jama.291.13.1563-a

No abstract available

PubMed Disclaimer

Comment on

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.
Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, Albain KS, Cella D, Wolf MK, Averbuch SD, Ochs JJ, Kay AC. Kris MG, et al. JAMA. 2003 Oct 22;290(16):2149-58. doi: 10.1001/jama.290.16.2149. JAMA. 2003. PMID: 14570950 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems
Medical
- MedlinePlus Health Information